VCEL · Vericel Corp
$46.62
-0.09 (-0.19%)
At close · Jul 29
Earnings today
Market Cap
$2.38B
Shares
51.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$46.62
Open$46.59
Day$45.68–47.07
52W$28.95–48.75
Avg vol 30d643K
Short int4.6M · 9.0% float · 9.1d
Short vol57%
Last earningsJul 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Earnings call today
Jul 30, 2026
Today
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
+13%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+26%
trailing
YTD return
+29%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
70 of 280 funds reported for Jun 30 · net +918.7K sh shares · +13 new
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Falling
9.01% of float · ▼ -6.3% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
280 holders — near 3-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
74%
expanding
EPS growth
+60%
Y/Y
Free cash flow
$24.7M
Valuation
P/E 108.4
rich
Balance sheet
$83.2M
net cash
Quant / Vol
risk profile
Volatility
48%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total revenue
· Full-year 2026
Maintained
$326M – $336M
prior FY $276.26M
midpoint +19.8% Y/Y
MACI revenue
· Full-year 2026
Initiated
$282M – $288M
Burn Care revenue
· Full-year 2026
Initiated
$44M – $48M
Gross margin
· Full-year 2026
Initiated
75%
Adjusted EBITDA margin
· Full-year 2026
Initiated
27%
Guided vs delivered
· last 2 settled
Total revenue
full-year
guided $272M – $276M
$276.26M
Beat +0.8%
Macy revenue
fourth-quarter
guided $82M – $84M
$92.92M
Beat +11.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
70 of 280 funds reported for Jun 30 · net +918.7K sh shares · +13 new
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Falling
9.01% of float · ▼ -6.3% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
280 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $29
Now $47 · 89%
52-wk high $49
vs 200-day avg +25%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA margin non-GAAP | 14% | first quarter ended March 31, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $15.1M | first quarter 2026 | — |
| Non-GAAP adjusted EBITDA non-GAAP | $9.6M | first quarter ended March 31, 2026 | — |
|
|
|||
| Operating cash flow | $16.4M | first quarter 2026 | — |
| Cash and investments | $200M | Q4 2025 | — |
| MACI Arthro trained surgeons | 1,000 | Full-Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCEL
this stock
Vericel Corp
|
$2.38B | +29.5% | +16.5% | 108.4 | 9.0% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCEL | +4.6% | +4.8% | +26.4% | +4.8% | +29.5% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +7.0% | +7.1% | +20.1% | +7.1% | +22.5% |
Key facts
CIK
887359
CUSIP
92346J108
13F (30d)
65 filings
65 filers
Visit website
Investor relations